The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nikitina E.A.

P.A. Herzen Moscow Research Oncology Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Troshenkov E.A.

P.A. Herzen Moscow Oncology Research Institute, Branch, P.A. Herzen Federal Medical Research Center, Ministry of Health of Russia, Moscow

Surkova V.S.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Tokaev V.K.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Glotov E.S.

P.A. Herzen Moscow Research Oncology Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kim Yu.A.

GBOU VPO «Rossijskij natsional'nyj issledovatel'skij meditsinskij universitet im. N.I. Pirogova» Minzdrava Rossii, Moskva, Rossija, 117997

Volchenko N.N.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena, Moskva

Malik D.S.

A.F. Tsyba Medical Radiology Research Center, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia

Platinum-based drugs in neoadjuvant treatment of patients with triple-negative breast cancer

Authors:

Nikitina E.A., Troshenkov E.A., Surkova V.S., Tokaev V.K., Glotov E.S., Kim Yu.A., Volchenko N.N., Malik D.S.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2020;9(2): 62‑67

DOI: 10.17116/onkolog2020902162

Read: 4676 times

Download PDF (RU)
Contact the author
Table of contents

PLATINUM-BASED DRUGS IN NEOADJUVANT TREATMENT OF PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER
PLATINUM-BASED DRUGS IN NEOADJUVANT TREATMENT OF PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

To cite this article:

Nikitina EA, Troshenkov EA, Surkova VS, et al. . Platinum-based drugs in neoadjuvant treatment of patients with triple-negative breast cancer. P.A. Herzen Journal of Oncology. 2020;9(2):62‑67. (In Russ.)
https://doi.org/10.17116/onkolog2020902162

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Prognostically unfa­vorable types of breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(6):78-82
Prognostic value of mole­cular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations. Russian Journal of Archive of Pathology. 2025;(3):88-96
TRPS1 as a novel immu­nohistochemical marker in breast cancer diagnosis. Russian Journal of Archive of Pathology. 2026;(1):80-87
Abstract:

Triple-negative breast cancer (TNBC) is an immunohistochemical type of breast cancer characterized by a lack of expression of estrogen and progesterone receptors, amplification in the Her2/neu gene, and a high Ki-67 proliferation index. This type of cancer has an aggressive course and is more common in women of childbearing age. According to various literature sources, from 25 to 60% of patients have BRCA-associated TNBC. Unlike other types of breast cancer, there is still no single concept in the treatment of this disease. The question of the inclusion of platinum-based drugs in the neoadjuvant therapy of TNBC is also a controversial issue. This review includes the results of clinical studies on this issue.

Keywords:

triple-negative breast cancer
neoadjuvant chemotherapy with the inclusion of platinum-based drugs
BRCA-associated triple-negative breast cancer

Authors:

Nikitina E.A.

P.A. Herzen Moscow Research Oncology Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Troshenkov E.A.

P.A. Herzen Moscow Oncology Research Institute, Branch, P.A. Herzen Federal Medical Research Center, Ministry of Health of Russia, Moscow

Surkova V.S.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Tokaev V.K.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Glotov E.S.

P.A. Herzen Moscow Research Oncology Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kim Yu.A.

GBOU VPO «Rossijskij natsional'nyj issledovatel'skij meditsinskij universitet im. N.I. Pirogova» Minzdrava Rossii, Moskva, Rossija, 117997

Volchenko N.N.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena, Moskva

Malik D.S.

A.F. Tsyba Medical Radiology Research Center, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia

Close metadata

References:

  1. Kaprin AD, Starinskiy VV, Petrova GV, eds. Zlokachestvennie novoobrazovaniya v Rossii v 2017 (zabolevaemost’ i smertnost’). M.: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2018. (In Russ.). Accessed September 12, 2019. Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf
  2. Swain S. Triple-negative breast cancer: metastatic risk and role of platinum agents. In: 2008 ASCO clinical science symposium. Chicago; 2008.
  3. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epi-demiology of basal like breast cancer. Breast Cancer Res Treat. 2008;109(1):123-139. Accessed September 12, 2019. https://doi.org/10.1007/s10549-007-9632-6
  4. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938-1948. Accessed September 12, 2019. https://doi.org/10.1056/NEJMra1001389
  5. Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomark Prev. 2012;21(1):134-147. Accessed September 12, 2019. https://doi.org/10.1158/1055-9965.EPI-11-0775
  6. Perou CM. Molecular stratification of triple negative breast cancer. Oncologist. 2010;15(suppl 5):39-48. Accessed September 12, 2019. https://doi.org/10.1634/theoncologist.2010-s5-39
  7. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Cont-reras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21(7):1688-1698. Accessed September 12, 2019. https://doi.org/10.1158/1078-0432.CCR-14-0432
  8. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767. Accessed September 12, 2019. https://doi.org/10.1172/JCI45014
  9. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, et al.; Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505-5512. Accessed September 12, 2019. https://doi.org/10.1158/1078-0432.CCR-12-3327
  10. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281. Accessed September 12, 2019. https://doi.org/10.1200/JCO.2007.14.4147
  11. Smirnova OV, Borisova VI, Gens GP. The evolution of know-ledge of triple-negative breast cancer: from biology to no-vel drug treatment. Malignant tumours/ Zlokachestvennie opucholi. 2017;(1):5-17. (In Russ.). Accessed September 12, 2019. https://doi.org/10.18027/2224-5057-2017-1-5-17
  12. Golshan M, Cirrioncione CT, Sikov WM, Berry DA, Jasinski S, Weisberg TF, Somlo G, et al. Impact of neoadjuvant chemothera-py in stage II—III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates. Ann Surg. 2015;262(3):434-439. Accessed September 12, 2019. https://doi.org/10.1097/SLA.0000000000001417
  13. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13-21. Accessed September 12, 2019. https://doi.org/10.1200/JCO.2014.57.0572
  14. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Somlo G, Port ER, Qamar R, Sturtz K, et al. Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/— carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB40603 (Allience). Cancer Res. 2016;76(4 suppl):2-5.
  15. Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, et al. Neoajuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomized phase 2 trial. Lancet Oncol. 2014;15(7):747-756. Accessed September 12, 2019. https://doi.org/10.1016/S1470-2045(14)70160-3
  16. Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378-1385. Accessed September 12, 2019. https://doi.org/10.1001/jamaoncol.2017.1007
  17. Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, et al. Comparison of neoadjuvant nab-paclitaxel + carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. J Natl Cancer Inst. 2017;110(6):628-637. Accessed September 12, 2019. https://doi.org/10.1093/jnci/djx258
  18. Sharma P, Lopez-Tarruella S, Garcia-Saenz J.A. et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018;24(23):5820-5829. Accessed September 12, 2019. https://doi.org/10.1158/1078-0432.CCR-18-0585
  19. Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203-217. Accessed September 12, 2019. https://doi.org/10.1016/j.breast.2017.07.017
  20. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28(8):1700-1712. Accessed September 12, 2019. https://doi.org/10.1093/annonc/mdy537
  21. Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers-systematic review and meta-analysis. Hered Cancer Clin Pract. 2019;17:11 Accessed September 12, 2019. https://doi.org/10.1186/s13053-019-0111-y
  22. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28(7):1145-1153. Accessed September 12, 2019. https://doi.org/10.1200/JCO.2009.22.4725
  23. Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33(17):1895-1901. Accessed September 12, 2019. https://doi.org/10.1200/JCO.2014.57.0085
  24. Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, et al. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early- stage breast cancer (NCT01372579). Breast Cancer Res Treat. 2015;151(3):629-638. Accessed September 12, 2019. https://doi.org/10.1007/s10549-015-3435-y
  25. Harma P, Lopez-Tarruella S, Garcia-Saenz JA, Ward C, Connor CS, Gomez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohort. Clin Cancer Res. 2017;23(3):649-657. Accessed September 12, 2019. https://doi.org/10.1158/1078-0432.CCR-16-0162
  26. Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497-509. Accessed September 12, 2019. https://doi.org/10.1016/S1470-2045(18)30111-6
  27. Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP. Evaluation of tolerability and efficacy of incorpora-ting carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort. Breast. 2018;40:141-146. Accessed September 12, 2019. https://doi.org/10.1016/j.breast.2018.05.007
  28. Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018;119(2):141-152. Accessed September 12, 2019. https://doi.org/10.1038/s41416-018-0127-5
  29. Fontaine C, Cappoen N, Renard V, Van Den Bulk H, Vuylsteke P, Glorieux P, De Greve J, Decoster L, Vanhoeij M, Awada A et al. Updated results of the breast cancer task force phase II study of neoadjuvant weekly carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts). Ann Oncol. 2017;28(suppl 5):168. Accessed September 12, 2019. https://doi.org/10.1093/annonc/mdx362.018
  30. Kim GM, Jeung HC, Jung KH, Kim SH, Kim HJ, Lee KH, Park KH, Lee JE, Ahn MS, Kohn S, et al. PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer. J Clin Oncol. 2017;35(15 suppl):TPS587. Accessed September 12, 2019. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS587
  31. Krasnov GS, Dmitriev AA, Snezhkina AV, Kudryavtseva AV. Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target. Expert Opin Ther Targets. 2013;17(6):681-693. Accessed September 12, 2019. https://doi.org/10.1517/14728222.2013.775253
  32. Oparina NY, Snezhkina AV, Sadritdinova AF, Dmitriev AA, Senchenko VN, Mel’nikova NV, Speranskaya AS, Darii MV, Stepanov OA, Kudryavtseva AV, Veselovskii VA, Barkhatov IM. Differential expression of genes that encode glycolysis enzymes in kidney and lung cancer in humans. Russian Journal of Genetics/Genetika. 2013;49(7):814-823. (In Russ). Accessed September 12, 2019. https://doi.org/10.1517/14728222.2013.775253
  33. Pudova EA, Snezhkina AV, Ermoschenkova MV, Kharitonov SL, Sukhotko AS, Fedorova MS, Sadritdinova AF, Guvatova ZG, Savvateeva EV, Melnikova NV, Nyushko KM, Dmitriev AA, Kaprin AD, Alekseev BY, Zikiryakhodjaev AD, Kudryavtseva AV. HK1 and HK2 gene expression in triple negative and luminal A breast cancer. Biologicheskie membrany. 2018;35(5):403-406. (In Russ). Accessed September 12, 2019. Available at: https://www.libnauka.ru/journal/biologicheskie-membranyi/?tab=2018
  34. Krasnov GS, Dmitriev AA, Sadritdinova AF, Fedorova MS, Snezhkina AV, Melnikova NV, Poteryakhina AV, Nyushko KM, Belyakov MM, Kaprin AD, Zaretsky AR, Kudryavtseva AV. Evaluation of hexokinase gene expression in colorectal cancer using bioinformatics tools. Biophysics. 2015;60(6): 1050-6. https://doi.org/10.1134/s0006350915060172
  35. Snezhkina AV, Krasnov GS, Zaretsky AR, Zhavoronkov A, Nyushko KM, Moskalev AA, Karpova IY, Afremova AI, Lipatova AV, Kochetkov DV, Fedorova MS, Volchenko NN, Sadritdinova AF, Melnikova NV, Sidorov DV, Popov AY, Kalinin DV, Kaprin AD, Alekseev BY, Dmitriev AA, Kudryavtseva AV. Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. BMC Genomics. 2016;17(suppl 14):1011. https://doi.org/10.1186/s12864-016-3351-5
  36. Kudryavtseva A, Zikiriakhodzhaev A, Ermoshchenkova M, Volchenko N, Sukhotko A, Belyakov M, Sudalenko O, Slavnova E, Kardymon O, Stepanov O, Karpova I, Fedorova M, Nikiforovoch P, Sadritdinova A, Nyushko K, Kalinin D, Melnikova N, Belova A, Popov A, Krasnov G, Alekseev B, Kaprin A, Snezhkina A. Up-regulation of HK2 expression is associated with poor prognosis of breast cancer luminal B type. FEBS J. 2016;283(suppl 1):87-88. https://doi.org/10.1111/febs.13807
  37. Ogawa H, Nagano H, Konno M, Eguchi H, Koseki J, Kawamoto K, Nishida N, Colvin H, Tomokuni A, Tomimaru Y, Hama N, Wada H, Marubashi S, Kobayashi S, Mori M, Doki Y, Ishii H. The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer. Mol Clin Oncol. 2015;3(3):563-571. https://doi.org/10.3892/mco.2015.490
  38. Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, Lee SC, Kim WJ. PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer. Urol Oncol. 2012;30(6):893-899. https://doi.org/10.1016/j.urolonc.2010.08.018
  39. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961-970. https://doi.org/10.3109/0284186X.2015.1043026
  40. Kudryavtseva AV, Fedorova MS, Zhavoronkov A, Moskalev AA, Zasedatelev AS, Dmitriev AA, Sadritdinova AF, Karpova IY, Nyushko KM, Kalinin DV, Volchenko NN, Melnikova NV, Klimina KM, Sidorov DV, Popov AY, Nasedkina TV, Kaprin AD, Alekseev BY, Krasnov GS, Snezhkina AV. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells. BMC Genet. 2016;7(suppl 3):156. https://doi.org/10.1186/s12863-016-0459-1
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.